logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Aditxt, Inc.

ADTX

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizeā€¦ read more

Healthcare

Biotechnology

3 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.00

Price

-2.91%

-$0.03

$1.03

Previous Close

$1.01

Open

Premium

52w Discount
Market Cap

$2.431m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$55.320k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$25.428m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$44,083.98

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$15.764m

$31.222m

Assets

$15.458m

Liabilities

$4.073m

Debt
Debt to Assets

13.0%

-

Debt to EBITDA
Free Cash Flow

-$22.515m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.